United States - English - NLM (National Library of Medicine)

mayne pharma inc. - flurandrenolide (unii: 8eul29xuqt) (flurandrenolide - unii:8eul29xuqt) - flurandrenolide ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of components of the preparation.

United States - English - NLM (National Library of Medicine)

mayne pharma inc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 10 mg - carbidopa and levodopa tablets usp are indicated in the treatment of parkinson's disease post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa. carbidopa and levodopa may be administe

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.5 mg

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.5%. however, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. norethindrone tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: - known or suspected pregnancy - known or suspected carcinoma of the breast - undiagnosed abnormal genital bleeding - hypersensitivity to any component of this product - benign or malignant liver tumors - acute liver disease

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7) - hydrocodone bitartrate 5 mg

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - disopyramide phosphate capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate capsules are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.5%. however, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. the following table lists the pregnancy rates for users of all major methods of contraception.    % of women experiencing an unintended pregnancy within the first year of use  % of women continuing use at one year3  method (1)  typical use1 (2)  perfect use2 (3) (4)  chance4  85  85    spermicides5  26  6  40  periodic abstinence  25    63     calendar    9       ovulation method    3       sympto-thermal6    2       post-ovulation    1    cap7           parous women  40  26  42     nulliparous women  20  9  56  sponge           parous women  40  20  42     nulliparous women  20  9  56  diaphragm7  20  6  56  withdrawal  19  4    condom8           female (reality)  21  5  56     male  14  3  61  pill  5    71

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate lotion is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. therefore, hydrocortisone butyrate lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topical human dose (mthd) for hydrocortisone butyrate lotion (25 g lotion). systemic embryofetal development studies were conducted in rats and rabbits. subcutaneous doses

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.15 mg - azurette® (desogestrel/ethinyl estradiol and ethinyl estradiol tablets usp) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. table ii: percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year, united states. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * (4) method   (1) typical use † (2) perfect use ‡   (3) chance§   85 85 spermicides¶ 26 6 40 periodi

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg - cyclosporine capsules, usp [modified] and cyclosporine oral solution, usp [modified] are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. cyclosporine capsules, usp [modified] and cyclosporine oral solution, usp [modified] have been used in combination with azathioprine and corticosteroids. cyclosporine capsules, usp [modified] and cyclosporine oral solution, usp [modified] are indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. cyclosporine capsules, usp [modified] and cyclosporine oral solution, usp [modified] can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. cyclosporine capsules, usp [modified] and cyclosporine oral solution, usp [modified] are indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque pso